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TheStandardmeasuresofexperimental arthritisfailtodetect, visualize,andquantifyearlyinﬂammationanddiseaseactivity. Here,
wedescribetheuseofaninjectableMMP-activatedﬂuorescenceagentforinvivoquantiﬁcationofacuteinﬂammationproduced by
collagen-antibody-induced arthritis(CAIA)inCCchemokinereceptor-2 (Ccr2−/−)nullmice.AlthoughCcr2−/− DBA1/Jmicewere
highly susceptible to and rapidly developed CAIA, the standard clinical assessment of fore or hind paw thicknesses was unable to
detect signiﬁcantacute inﬂammatorychanges (days3–10).Remarkably, noninvasive,in situ, MMP-activatableﬂuorescentimaging
of Ccr2−/− DBA1/J mice with CAIA displayed acute joint pathology in advance of clinically measurable acute inﬂammation (days
5,7, and 10).These results were conﬁrmed by the histologyofanklejoints,which showed signiﬁcantinﬂammation,bone loss,and
synovial hyperplasia, compared to control mice at postimmunization day 5. The MMP-mediated ﬂuorescence technique holds
tremendous implications for quantiﬁable examination of arthritis disease activity of acute joint inﬂammation.
1.Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory joint
disease with a substantial morbidity and mortality that af-
fects approximately 1% of the US population [1, 2]. Clini-
cally, RA manifests as unrelenting pain, stiﬀness, progressive
joint destruction, and functional disability, in addition to
creating a huge burden for caregivers and impairing pro-
ductivity [3]. Although the etiology of RA is not completely
delineated,studiesusing animal modelsofarthritis led to the
development of novel biological agents for the treatments
of arthritis [4, 5]. However, treatment success is limited by
early diagnosis and early therapeutic interventions. What is
more, by the time the signs of arthritis appear in the models
of RA, the disease well passes the acute phase of the disease.
To complicatethings further the classical measures of disease
activity (clinical scoring and alterations to paws) rely heavily
on subjective, nonclinicalmeasures ofinﬂammatory changes
(paw thickness and joint histology) and fail to impart acute
quantitative measures of RA disease progression.
Recently, we described a protective role for CCR2 against
collagen-induced arthritis (CIA) in mice [6, 7]. CCR2-null
mice (Ccr2−/−) displayed greater incidence and severity of
experimental arthritis compared to wild-type controls [6].
Ccr2−/− mice developed extensive joint inﬂammation and
histopathological features of reminiscent of RA with an en-
hanced CCR2-independent recruitment of neutrophils and
monocytes/macrophages.Duringinﬂammation, CCR2isex-
pressed on the surface of monocytes, macrophages, T and B
lymphocytes, natural killer cells, and dendritic cells to direct
CCR2-mediated chemotaxis [8]. Coincident with the accu-
mulation of inﬂammatory cells, the expression of matrix
metalloproteinases (MMPs) also increases in early stages of
arthritis [9, 10]. In the present study, we hypothesized that2 International Journal of Inﬂammation
MMP-activatable ﬂuorescent in vivo imaging could serve
as a marker of acute inﬂammation and early arthritis of
CAIA in Ccr2−/− mice. Our ﬁndings demonstrating the
utility of an MMP-activated ﬂuorescence agent not only
provided a sensitive method for monitoring and imaging
clinical synovitis, but also aﬀorded us the ability to quantify
inﬂammation prior to visible synovitis.
From our ﬁndings, we propose an alternative method for
monitoring disease activity in RA disease models via tar-
geted ﬂuorescent imaging of protease activity. Compared to
the standard measures of disease progression, ﬂuorescence
imaging quickly discriminated early inﬂammation and was
more sensitive than the standard clinical measures of acute
inﬂammation in experimental arthritis.
2.Materialsand Methods
2.1. Mice. Mice were housed under a pathogen-free envi-
ronment at the University of Texas Health Science Center
at San Antonio, Tex, USA and procedures were performed
according to the protocol approved by the Institutional
AnimalCareandUseCommittee.MaleCcr2−/− DBA1/Jmice
(6–8 weeks old) were developed as previously described [6].
2.2. Collagen-Antibody-Induced Arthritis (CAIA) Immuniza-
tion. To examine early inﬂammation in CAIA, mice were
injected with the collagen type II antibody, previously de-
scribed by Quinones et al. [6]. Brieﬂy, on day 0 mice received
an intravenous injection of an antibody cocktail (4mg)
consisting of four mouse antibodies to collagen type II
(Chemicon International, Temecula, Calif, USA) at the base
of the tail. On day 3, mice received a single intraperitoneal
injection of 25μg lipopolysaccharide (LPS; Escherichia coli,
serotype O55:B5; Sigma, St. Louis, MO) in 0.9% sterile
saline.
2.3. In Vivo Fluorescent Imaging and Quantiﬁcation. Twenty-
four hours prior to imaging, CAIA/LPS-treated Ccr2−/−
DBA1/J mice (n = 3) and control mice (n = 2) received
an intramuscular injection of ketamine hydrochloride
(10mg/kg) to immobilize the mice. Immediately, the mice
receivedoneintravenousinjection(20nmol/μL)ofanMMP-
activatable (excitation: 680nm; emission: 700nm) ﬂuores-
cent in vivo imaging agent (MMPsense 680, VisEn Medical,
Woburn, Mass, USA) that remained optically silent in an
unactivated state. Protease activation produced ﬂuorescence
(inﬂammatory-disease-state-activated, in situ). Control mice
(n = 2) received phosphate-buﬀered-saline (PBS). This pro-
cedure was repeated on days 7 and 10. Fluorescence imaging
was performed (excitation: 675nm; emission: 720nm) using
the IVIS spectrum imaging platform (Caliper Life Sciences,
Hopkinton, Mass, USA) with an excitation of 675nm and
an emission of 720nm wavelengths in epi-illumination and
transillumination modes in vivo.I magesw er ecaptur edusing
a CCD camera. Macrophage and neutrophil recruitment
was quantiﬁed by measuring the ﬂuorescence intensity
(photons/second) produced by MMPsense 680 activation at
the paw inﬂammation.
2.4. Clinical Assessment. The severity of arthritis was scored
based on clinical scoring of the hind and fore paws, as previ-
ously described [6]. Brieﬂy, the joint swelling was assigned a
clinicalscoregradedontheseveritywhereswelling/erythema
of hind and fore paws was graded from 0 (no swelling or
erythema) to grade 4 (severe swelling with joint rigidity or
deformity). The ﬁnal clinical score (severity) was reported as
the mean joint involvement from the hind and fore paws.
2.5. Histopathology. To determine the extent of disease de-
struction, the ankle joints were collected from CAIA/LPS-
treated and control mice, the skin removed, washed in
PBS, and joints ﬁxed overnight in paraformaldehyde (4%
in PBS, pH 7.2). The bone was decalciﬁed in 10% EDTA
and followed by paraﬃn tissue embedding, serial sectioning
(5μm), and stained with hematoxylin and eosin (H&E).
Paraformaldehyde, EDTA, hemotoxylin, and eosin were ob-
tained from Sigma, St. Louis, Mo, USA.
2.6. Statistical Analyses. Data are presented as mean ± SEM.
Groups were analyzed using Stata (StataCorp, College Sta-
tion, TX) with statistical signiﬁcance at P ≤ .05. Nonpar-
ametric statistical analyses with Spearman correlation for
nonparametric data (paw thickness and photons/second)
were performed with the Bonferroni correction.
3.Results
3.1. Clinical Assessment of CAIA. The development of acute
arthritis in CAIA is dependent on the innate immunity,
and the disease is primarily mediated by neutrophils and
macrophages; therefore, we examined the onset of disease
very early (days 3–10) by standard measures of clinical
assessment. The susceptibility to arthritis, as represented by
theclinicalscore,forCAIA-treatedCcr2−/− DBA1/Jmiceand
control(DBA1/J)miceimmunizedwithacocktailofcollagen
type II antibodies (day 0) was examined and a progressive
increase in arthritis shown was. At its greatest susceptibility,
the clinical score reached a value of 6 at day 10 compared to
control mice that which showed no evidence of disease
(Figure 1(a)). An examination of the fore and hind paw
thicknesses showed no signiﬁcant diﬀerence between the
CAIA mice and control animals (Figures 1(b)-1(c))a c r o s s
days 3–10, except for a signiﬁcant diﬀerence in the fore paws
at day 3 that was not signiﬁcant at later days.
3.2. Protease Activity Assessment of CAIA. We next hypoth-
esized that the acute inﬂammatory changes seen in CAIA
Ccr2−/− DBA1/Jmice manifested sooner than clinically mea-
surable once (paw thickness) and would only be detectable
by in vivo, MMP-activatable ﬂuorescent imaging. In line
with our hypothesis, precise in situ quantiﬁcation of acute
inﬂammation was detected in the arthritic fore and hind
paws. We employed protease-targeted ﬂuorescence imaging
to look for evidence of acute inﬂammation in CAIA of
Ccr2−/− DBA1/J(n = 3)and control mice (n = 2)(Figure2).
Mice received an intravenous injection of MMPsense 680
(protease-activated ﬂuorescent probe) to directly quantifyInternational Journal of Inﬂammation 3
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Figure 1: Clinical assessment of Ccr2−/− DBA1/J animals after receiving CAIA. The development of RA was examined clinically. Mice
received immunization intravenously with collagen type II antibody or PBS (day 0) followed by lipopolysaccharide stimulation or with
saline for control (day 3). (a) Increased susceptibility to arthritis in mice immunized (day 0) with collagen type II antibody (CAIA: n = 3)
compared to control mice (PBS: n = 2) without a signiﬁcant change in fore or hind paw thickness (b-c). Data is represented as the mean ±
SD.
inﬁltrating neutrophils and macrophages during acute in-
ﬂammation. A comparison of the mean ﬂuorescence inten-
sity (MFI; photons/second), produced from the local activa-
tion of proteases, produced an intense signal in the inﬂamed
synovium in the fore and hind paws of Ccr2−/− DBA1/Jmice
but not control mice (Figure 2). An increase in the MFI was
seen across days 5, 7, and 10 in CAIA mice (bottom panel)
compared to control animals (top panel). Forexample, acute
inﬂammation in CAIA of Ccr2−/− DBA1/J mice peaked on
day 7 at (4.33E ± 09 MFI) and then moved towards re-
solutionofinﬂammation atday 10(1.92E ± 09MFI).On the
other hand, control mice maintained a consistent degree of
activationatday5(0.69E±09MFI),day7(0.59E±09MFI),
andday10(0.55E±09MFI).Notably ,therewasanincreased
ﬂuorescence activity (designated by the asterisk in Figure 2)
in the fore and hind paws that was not previously detectable4 International Journal of Inﬂammation
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Figure 2: In vivo quantiﬁcation of protease activation in acute arthritis. Comparison of the mean ﬂuorescence intensity in acute in-
ﬂammation in CAIA mice, in vivo. Hind and fore paw inﬂammation recruited activated monocytes and neutrophils in Ccr2−/− DBA1/J
(n = 3) mice. Recruited cells were visualized with MMPsense 680, a molecular probe that ﬂuoresces upon speciﬁc cleavage by MMP 2, 3,
9, and 13, imaged on IVIS spectrum at excitation of 675nm and emission of 720nm. ∗The right paws and hind feet of the mice increased
activity as seen by the values, but the inﬂammationwas not visually apparent. Photons are listed, data presented as mean ± SD.
by the conventional measures of arthritis (i.e., clinical score,
paw thickness, and histology).
3.3. Histological Assessment of CAIA. To conﬁrm the inﬂam-
matory changesdetected by ﬂuorescenceimaging ofprotease
activity, we performed histological analysis on the arthritic
ankle joints of Ccr2−/− DBA1/J and control mice (Figure 3).
In the CAIA model, arthritis resolves by days 10–14, so we
chose postimmunization day 5 to discriminate histological
changes in CAIA. The ankle joints were formalin ﬁxed,
embedded in paraﬃn, sectioned for histology, and stained
with hemotoxylin and eosin. Arthritis in CAIA of Ccr2−/−
DBA1/J mice resulted in the marked elevation of neutrophil
inﬁltrates, bone and cartilage erosion, pannus formation,
and ﬁbrin deposition (Figure 3, bottom panel) whereas con-
trol animals did not show any of these alterations (Figure 3,
top panel). Overall, the acute changes in CAIA mice con-
ﬁrmed the acute inﬂammation detectable by the in vivo
MMP-activatable ﬂuorescent imaging, whereas the control
mice showed no signiﬁcant histological changes.
4.Discussion
Our study utilized an MMP-mediated ﬂuorescence imaging
agent to detect acute and early inﬂammation in CAIA. We
demonstrated that MMPsense 680 targeted the inﬂamed
synovium in CAIA and that protease activity precisely
corresponded to acute inﬂammation in advance of clinical
detection (paw thickness) of disease activity. The use of the
protease-activatableimagingagentmadeitpossibletovisual-
izeandquantifyearlyinﬂammatory events(days5,7,and10)
outside the conventional methods of measuring disease that
rely heavily on subjective assessments. Fluorescent protease
imaging proved capable of discriminating acute inﬂamma-
tion in arthritic Ccr2−/− DBA1/J mice.
At early stages of arthritis, there appears to be a window
of opportunity for when immune dysfunction in RA may
potentially be reversible [11]. This window exists at the time
prior to the development of histological evidence of pannus
and joint damage. However, there does not exist a clinical
method of detecting acute events in arthritis with such
sensitivity. Much eﬀort has been done to identify biomarkers
to detect and possibly quantify the severity of RA disease.
Clinically, the most commonly measured markers of in-
ﬂammation are C-reactive protein (CRP) and ESR [11]. Ex-
perimentally,theRFandanticollagenantibodiesarethemost
common measured biomarkersofinﬂammation. Yet, neither
holdssuﬃcient sensitivity to be meaningful for acutestage of
disease detection.
To date, current research eﬀorts do not suﬃciently mea-
sure early events of acute inﬂammation in arthritis although
such knowledge is critical for detecting arthritis early, devel-
oping novel intervention that targets early events, and mon-
itoring disease remission. Adding to this problem is the fact
that most studies utilizing experimental models of arthritis
w e r el i m i t e db yt h eu s eo fs t a n d a r dc l i n i c a l( c l i n i c a ls c o r -
ing/grading and thickness/volume measures) or traditional
post mortem (histology) assessments to measure arthritis
which were not sensitive enough to detect and quantiﬁably
measure early inﬂammation over the course of the disease.
MMP-mediated monitoring of early arthritis may enable
early monitoring of inﬂammatory events and holds the
potential for transforming the interpretation of research ef-
forts in arthritis models.
5.Conclusion
Protease-activatable imaging agents are potent tools that af-
ford non invasive, in vivo, in situ, and quantiﬁable mea-
sures of arthritis progression and are speciﬁcally sensitiveInternational Journal of Inﬂammation 5
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Figure 3: Histologicalﬁndings after CAIA administration.Mice were immunized with collagen type II antibody or PBS (day 0) followed by
lipopolysaccharide stimulation or received saline as a control on day 3. On day 5, ankle joints were ﬁxed in formalin, paraﬃn-embedded,
sectioned, and stained with hemotoxylin and eosin. (Top panel) Representative histology with acute inﬂammation showing increased
synovial hyperplasia, bone and cartilage destruction, pannus invasion, and ﬁbrin deposition (bottom panel) in Ccr2−/− DBA1/J mice,
compared to no acute inﬂammationin control mice treated with PBS at day 0 and saline at day 3 (bottom panel). Results are representative
of independent experiments with 2-3 mice/group.
enough to detect early stages of disease. While the imaging
technology is not applicable for clinical use, it does aﬀord a
powerful tool forassessing modelsofRAtogainnovel spatial
and temporal insights into arthritis disease progression,
henceenhancingtheunderstandingofmolecularandcellular
mechanisms underlying RA with the potential for expanding
assessments for treatments.
Abberviation
MMP: Matrix metalloproteinase
DC: Dendritic cells
RA: Rheumatoid arthritis
CAIA: Collagen antibody induced arthritis
LPS: Lipopolysaccharide.
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